http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2558842-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate | 2009-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f630e9fd331d2cff828fa4ce73106546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcbaf0d8ff1a66ae5d8442e841847a70 |
| publicationDate | 2016-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2558842-T3 |
| titleOfInvention | Mixed agonists based on GIP for the treatment of metabolic disorders and obesity |
| abstract | Glucagon analogue (SEQ ID NO: 1) that has GIP agonist activity, with the following modifications: (a) an amino acid modification in position 1 that confers GIP agonist activity, optionally, in which the amino acid in position 1 is an amino acid that lacks an imidazole side chain; (b) one, two, three or all amino acids at positions 16, 20, 21 and 24 of the analog are substituted by an amino acid a, a-disubstituted, (c) amino acid modifications at one, two or all positions 27 , 28 and 29, and (d) 1-9 additional amino acid modifications in relation to the glucagon sequence (SEQ ID NO: 1), in which the EC50 of the analog for GIP receptor activation is approximately 10 nM or less, and in which the EC50 of the analog in the GIP receiver is less than about 50 times different from its EC50 in the GLP-1 receiver, optionally, in which the GIP power of the analog is within about 15 times of the GLP-1 potency of the analog. |
| priorityDate | 2008-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.